Laurent O Mosnier1. 1. Department of Molecular Medicine (IMM-315), The Scripps Research Institute, La Jolla, California, USA.
Abstract
PURPOSE OF REVIEW: Activated protein C (APC) is a homeostatic coagulation protease with anticoagulant and cytoprotective activities. Focusing on APC's effects in the brain, this review discusses three different scenarios that illustrate how APC functions are intimately affecting the physiology and pathophysiology of the brain. RECENT FINDINGS: Cytoprotective APC therapy holds promise for the treatment of ischemic stroke, and a recently completed trial suggested that cytoprotective-selective 3K3A-APC reduced bleeding in ischemic stroke patients. In contrast, APC's anticoagulant activity contributes to brain bleeding as shown by the disproportional upregulation of APC generation in cerebral cavernous malformations lesions in mice. However, too little APC generation also contributes to maladies of the brain, such as in case of cerebral malaria where the binding of infected erythrocytes to the endothelial protein C receptor (EPCR) may interfere with the EPCR-dependent functions of the protein C pathway. Furthermore, discoveries of new activities of APC such as the inhibition of the NLRP3-mediated inflammasome and of new applications of APC therapy such as in Alzheimer's disease and graft-versus-host disease continue to advance our knowledge of this important proteolytic regulatory system. SUMMARY: APC's many activities or lack thereof are intimately involved in multiple neuropathologies, providing abundant opportunities for translational research.
PURPOSE OF REVIEW: Activated protein C (APC) is a homeostatic coagulation protease with anticoagulant and cytoprotective activities. Focusing on APC's effects in the brain, this review discusses three different scenarios that illustrate how APC functions are intimately affecting the physiology and pathophysiology of the brain. RECENT FINDINGS: Cytoprotective APC therapy holds promise for the treatment of ischemic stroke, and a recently completed trial suggested that cytoprotective-selective 3K3A-APC reduced bleeding in ischemic strokepatients. In contrast, APC's anticoagulant activity contributes to brain bleeding as shown by the disproportional upregulation of APC generation in cerebral cavernous malformations lesions in mice. However, too little APC generation also contributes to maladies of the brain, such as in case of cerebral malaria where the binding of infected erythrocytes to the endothelial protein C receptor (EPCR) may interfere with the EPCR-dependent functions of the protein C pathway. Furthermore, discoveries of new activities of APC such as the inhibition of the NLRP3-mediated inflammasome and of new applications of APC therapy such as in Alzheimer's disease and graft-versus-host disease continue to advance our knowledge of this important proteolytic regulatory system. SUMMARY:APC's many activities or lack thereof are intimately involved in multiple neuropathologies, providing abundant opportunities for translational research.
Authors: Eimear M Gleeson; María G Dichiara; Agustina Salicio; Louise M Quinn; Clive Drakeford; Shane E Russell; Patrick T Walsh; Josune Orbe; José Hermida; Owen P Smith; James S O'Donnell; Ramón Montes; Roger J S Preston Journal: Blood Date: 2015-06-17 Impact factor: 22.113
Authors: Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler Journal: Blood Date: 2015-09-04 Impact factor: 22.113
Authors: Patrick Lyden; Howard Levy; Sara Weymer; Kent Pryor; William Kramer; John H Griffin; Thomas P Davis; Berislav Zlokovic Journal: Curr Pharm Des Date: 2013 Impact factor: 3.116
Authors: Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn Journal: Nature Date: 2016-03-30 Impact factor: 49.962
Authors: Bilgimol Chumappumkal Joseph; Byron Y Miyazawa; Charles T Esmon; Mitchell J Cohen; Annette von Drygalski; Laurent O Mosnier Journal: Blood Adv Date: 2022-02-08